Teva Pharmaceuticals USA Responds to FDA Findings on Budeprion XL 300 Mg
Posted on: Wednesday, 16 April 2008, 15:00 CDT
Teva Pharmaceuticals USA issues the following statement in response to the "Review of Therapeutic Equivalence Generic Bupropion XL 300 mg and Wellbutrin XL 300 mg" released by FDA on April 16, 2008:
As the largest generic drug company in the world, Teva's first priority is to ensure that patients receive products with unquestioned safety and effectiveness. Teva Pharmaceutical Industries Ltd. is committed to making affordable, quality healthcare accessible to patients. We constantly work to ensure that all of our products meet FDA's comprehensive regulations governing the review and approval of generic drugs.
Teva commends the actions taken by the FDA, to assure patients that Budeprion is both "bioequivalent and therapeutically equivalent to (interchangeable with) Wellbutrin XL 300 mg." Teva is pleased that after their thorough review of Budeprion, the FDA has released this important information to the public.
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the world's leading generic pharmaceutical company. The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80 percent of Teva's sales are in North America and Europe.
The full FDA Report can be viewed at: http://www.fda.gov/cder/drug/infopage/bupropion/TE_review.htm.
Source: Business Wire
Related Articles
- Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R)
- FDA Grants Priority Review for Millennium's Myeloma Drug
- Teva Specialty Pharmaceuticals and UCB Announce U.S. Respiratory Collaboration Agreement
- FDA Accepts for Review NDA Filing for Zensana(TM) (Ondansetron HCI) Oral Spray
- FDA Clears a Generic Biotech Drug
- FDA Grants Priority Review for Bristol-Myers Squibb's Investigational Oncology Treatment Dasatinib
- Pfizer Petitions FDA to Recall Teva and Sandoz Generic Azithromycin Products to Correct Misbranding
- FDA Grants Priority Review for Rituxan(R) Supplemental Biologics License Application for Front-Line Treatment of Intermediate-Grade or Aggressive Non-Hodgkin's Lymphoma
- Xanodyne Pharmaceuticals Completes Acquisition of aaiPharma Products
 |
 |
User Comments (0)
RSS Feeds